Jeena Sikho Lifecare launches Narie Xpert and Porush Xpert Ayurvedic products
- Jeena Sikho Lifecare launched six new Ayurvedic products on September 2, 2026
- New range includes Narie Xpert and Porush Xpert in granule, syrup, and tablet forms
- All products are targeted exclusively at the domestic Indian market
- Disclosure made under SEBI LODR Regulation 30 and recent circulars

*this image is generated using AI for illustrative purposes only.
Jeena Sikho Lifecare launched six new Ayurvedic healthcare products on September 2, 2026. The company introduced the Narie Xpert and Porush Xpert ranges to expand its domestic wellness portfolio.
The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also referenced SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
Product Portfolio Expansion
The new offerings target specific health concerns within the Ayurvedic segment. Each product line is available in three formats: granules, syrup, and tablets.
| Product Name | Format | Size |
|---|---|---|
| Narie Xpert | Granules | 80g |
| Narie Xpert | Syrup | 500 ml |
| Narie Xpert | Tablet | 52 Tab |
| Porush Xpert | Granules | 80g |
| Porush Xpert | Syrup | 500 ml |
| Porush Xpert | Tablet | 52 Tab |
Market Focus
All six products are designated for the domestic market only. The filing explicitly states that international launch details are not applicable at this stage.
The company operates over 120 Ayurveda clinics and hospitals. It positioned these launches as part of its broader strategy to provide drug-free healthcare solutions.
Historical Stock Returns for Jeena Sikho Lifecare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.03% | -0.51% | -12.37% | -15.61% | -27.21% | 0.0% |
How might the exclusive domestic focus of the Narie Xpert and Porush Xpert ranges impact Jeena Sikho Lifecare's revenue diversification strategy in the near term?
What is the projected timeline for potential international expansion, and what regulatory hurdles must be cleared for these Ayurvedic products to enter global markets?
How do analysts expect the integration of these new product lines into the company's 120+ clinic network to influence patient retention and average transaction values?


































